Stock 7595 PHARMIGENE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pharmigene, Inc.

Equities

7595

TW0007595B13

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-05-16 EDT 		5-day change 1st Jan Change
17.5 TWD -2.78% Intraday chart for Pharmigene, Inc. -5.41% -15.46%
04-30 Pharmigene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Pharmigene, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 1,087 943.2 862.8 1,045
Enterprise Value (EV) 1 810.8 718.8 676.6 1,435
P/E ratio -75.5 x -40.2 x -20.2 x -12.9 x
Yield - - - -
Capitalization / Revenue 10.7 x 7.29 x 6.45 x 7.87 x
EV / Revenue 8 x 5.56 x 5.06 x 10.8 x
EV / EBITDA -92.8 x -49.1 x -21.4 x -39.5 x
EV / FCF -44.1 x -29.5 x -34.6 x -2.05 x
FCF Yield -2.27% -3.39% -2.89% -48.8%
Price to Book 2.65 x 2.47 x 2.54 x 2.21 x
Nbr of stocks (in thousands) 43,465 43,465 43,465 50,465
Reference price 2 25.00 21.70 19.85 20.70
Announcement Date 21-04-26 22-05-19 23-04-06 24-04-30
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 77.8 65.28 101.4 129.4 133.8 132.7
EBITDA 1 -7.559 -25.9 -8.735 -14.63 -31.67 -36.32
EBIT 1 -12.46 -30.65 -13.87 -22.74 -44.45 -59.18
Operating Margin -16.01% -46.95% -13.69% -17.58% -33.22% -44.6%
Earnings before Tax (EBT) 1 -12.57 -35.32 -9.495 -23.77 -42.7 -72.63
Net income 1 -13.39 -35.11 -11.21 -23.43 -42.72 -72.65
Net margin -17.21% -53.78% -11.06% -18.12% -31.93% -54.74%
EPS 2 -0.6100 -1.600 -0.3312 -0.5400 -0.9828 -1.600
Free Cash Flow 1 -10.36 -10.61 -18.38 -24.35 -19.55 -699.7
FCF margin -13.32% -16.26% -18.13% -18.83% -14.61% -527.27%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 20-09-21 20-09-21 21-04-26 22-05-19 23-04-06 24-04-30
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - 390
Net Cash position 1 127 79.6 276 224 186 -
Leverage (Debt/EBITDA) - - - - - -10.74 x
Free Cash Flow 1 -10.4 -10.6 -18.4 -24.4 -19.6 -700
ROE (net income / shareholders' equity) -7.76% -23.7% -4.15% -5.92% -11.8% -18.5%
ROA (Net income/ Total Assets) -4.23% -10.8% -2.79% -3.27% -6.92% -5.17%
Assets 1 316.8 325.7 402.1 716.6 617.6 1,405
Book Value Per Share 2 7.550 5.950 9.420 8.790 7.820 9.380
Cash Flow per Share 2 2.220 2.060 4.900 2.400 1.770 1.450
Capex 1 11.9 0.64 8.85 12.7 10.5 665
Capex / Sales 15.3% 0.98% 8.73% 9.79% 7.85% 501.34%
Announcement Date 20-09-21 20-09-21 21-04-26 22-05-19 23-04-06 24-04-30
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
PHARMIGENE, INC. Stock Pharmigene, Inc.
-15.46% 27.43M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-31.90% 9.3B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-6.25% 3.1B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+25.95% 2.87B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-13.96% 2.17B
VERACYTE, INC. Stock Veracyte, Inc.
-16.83% 1.75B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+72.82% 1.5B
CAREDX, INC Stock CareDx, Inc
+29.17% 807M
SEEGENE, INC. Stock Seegene, Inc.
-2.62% 759M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-26.33% 532M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. 7595 Stock
  4. Financials Pharmigene, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW